(PharmaNewsWire.Com, April 26, 2019 ) The "Global Immuno-oncology Drugs Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of immuno-oncology drugs market with detailed market segmentation by drug type, therapeutic application, end user and geography. The global immuno-oncology drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading immuno-oncology drugs market players and offers key trends and opportunities in the market.
The immuno-oncology drugs market is anticipated to grow in the forecast, owing to the factors such as increasing prevalence of cancer, growing immune-oncology therapies, technological advancement in the field of drug discovery and increasing awareness amongst the patients. However, high cost of the treatment and risk associated with the treatment hampers the growth of the market.
Oncology medications are flourishing business for the pharmaceutical industry. Almost the major market players in this field are either manufacturing oncology drugs or have oncology medications in their pipeline as potential medications to sell in the coming years. Cancer affects millions of people across the globe. Robust research and development activities are going on to develop new drug entity in order to treat cancer. Based on their function of these drugs, they are further classified into subtypes such as radiolabeled antibodies, chemo labeled antibodies and bispecific monoclonal antibodies.
The List of Companies
1. Amgen, Inc. 2. Astrazeneca Plc 3. Bristol-Myers Squibb 4. Celgene Corporation 5. Eli lilly and Company 6. Sanofi 7. F. Hoffmann-La Roche 8. Novartis AG 9. Abbvie, Inc. 10. Pfizer Inc.
The global immuno-oncology drugs market is segmented on the basis of drug type, therapeutic application, end user. Based on drug type, the market is segmented as immune checkpoint inhibitors, monoclonal antibodies, cytokine based immunotherapy, cancer vaccines, Car-T cell therapy. On the basis of therapeutic application, the global immuno-oncology drugs market is segmented into melanoma, lung cancer, blood cancer, renal cell carcinoma, prostate cancer, bladder cancer, others. The end user segment is further segmented into hospitals, clinics, ambulatory surgical centers.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Iimmuno-oncology drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Immuno-oncology drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Immuno-oncology drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the immuno-oncology drugs market in these regions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
